GlassScriptPhysician profile
Jeffrey M Geitz
NPI 1124246855
$6,379.59
in general payments reported to CMS, 2019-2025
65 companies · $1,430 in 2025
The $1,430 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,228 · 2020: $465 · 2021: $76.91 · 2022: $967 · 2023: $1,005 · 2024: $1,208 · 2025: $1,430.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,643.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,642.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| US Oncology Corporate, INC. | $841.88 | 2022 | |
| Novartis Pharmaceuticals Corporation | $417.42 | 2019-2025 | |
| Janssen Biotech, INC. | $332.85 | 2019-2025 | Erleada, Darzalex, Tecvayli |
| Pfizer INC. | $316.16 | 2019-2025 | |
| Seagen INC. | $286.53 | 2019-2023 | Tukysa |
| Astrazeneca Pharmaceuticals LP | $279.61 | 2019-2025 | Imfinzi, Enhertu, Calquence |
| Incyte Corporation | $268.38 | 2019-2025 | Monjuvi, Jakafi, Zynyz |
| Celgene Corporation | $246.98 | 2019-2025 | Pomalyst, Reblozyl, Opdualag |
| Merck Sharp & Dohme LLC | $232.25 | 2019-2025 | Keytruda, Lynparza, Welireg |
| E.R. Squibb & Sons, L.L.C. | $223.39 | 2019-2025 | Opdivo, Opdualag, Krazati |
| Genentech USA, INC. | $200.62 | 2019-2025 | Tecentriq, Polivy, Lunsumio |
| Gilead Sciences, INC. | $162.60 | 2021-2025 | Trodelvy |
| Exelixis INC. | $122.11 | 2023-2025 | Cabometyx |
| Takeda Pharmaceuticals U.S.A., INC. | $121.27 | 2019-2025 | Ninlaro, Alunbrig, Iclusig |
| Eisai INC. | $119.28 | 2019-2025 |
Show all 65 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffrey Geitz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.